Assessment of racial and ethnic differences of atopic dermatitis severity and treatment patterns in a diverse outpatient cohort in the United States: a retrospective observational study.
Atopic dermatitis
Diverse
Eczema
Hispanic
Race
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
16
04
2023
accepted:
02
08
2023
revised:
18
07
2023
medline:
2
11
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Previous population-based studies in the United States found racial/ethnic differences of atopic dermatitis (AD) severity and treatment patterns. It is unclear whether these differences are from differences of disease characteristics or disparities. To examine racial/ethnic differences in severity and treatment patterns in a diverse outpatient patient cohort of AD patients (n = 833). There were no significant associations of highest-reported body surface area (BSA; Fisher's exact test, P = 0.19 and P = 0.44) or physician's global assessment (PGA; P = 0.63 and P = 0.57) with race or ethnicity; nor interactions of race/ethnicity with gender or age as predictors of BSA or PGA. Asian and multiracial/other patients were more likely than White or Black patients to use topical calcineurin inhibitors (Chi-square, P = 0.01). Dupilumab use differed by race (Multiracial/other = 35.0%; White = 20.1%; Asian = 15.7%; Black = 13.6%; Chi-square, P = 0.03), but not ethnicity (P = 0.88). Use of oral corticosteroids (Chi-square, P = 0.74), immunosuppressants (P = 0.98) or GABAergics (P = 0.16) or NBUVB (P = 0.42) did not differ by race. There were no interactions of race/ethnicity with gender or age as predictors of treatment use. Similar treatment patterns were observed across racial/ethnic groups. Though, topical calcineurin inhibitors were more commonly used in Asian and multiracial/other patients; dupilumab use was more common in multiracial/other patients.
Identifiants
pubmed: 37589796
doi: 10.1007/s00403-023-02696-1
pii: 10.1007/s00403-023-02696-1
doi:
Substances chimiques
Calcineurin Inhibitors
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2829-2832Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Hsu DY, Dalal P, Sable KA et al (2017) Validation of international classification of disease ninth revision codes for atopic dermatitis. Allergy 72(7):1091–1095. https://doi.org/10.1111/all.13113
doi: 10.1111/all.13113
pubmed: 27997983
Sanfilippo E, Iyer S, Patel N, Silverberg JI (2023) Assessment of racial differences of atopic dermatitis characteristics in a diverse outpatient cohort in the United States. Br J Dermatol 188(Supplement_2):ljac140.010. https://doi.org/10.1093/bjd/ljac140.010
doi: 10.1093/bjd/ljac140.010
Narla S, Silverberg JI (2021) Dermatology for the internist: optimal diagnosis and management of atopic dermatitis. Ann Med 53(1):2165–2177. https://doi.org/10.1080/07853890.2021.2004322
doi: 10.1080/07853890.2021.2004322
pubmed: 34787024
pmcid: 8604464
Croce EA, Lopes F, Ruth J, Silverberg JI (2021) Interventions to improve primary care provider management of atopic dermatitis: a systematic review. Pediatr Dermatol 38(5):1004–1011. https://doi.org/10.1111/pde.14667
doi: 10.1111/pde.14667
pubmed: 34263478
pmcid: 8578192
Eichenfield LF, Tom WL, Chamlin SL et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 70(2):338–51. https://doi.org/10.1016/j.jaad.2013.10.010
doi: 10.1016/j.jaad.2013.10.010
pubmed: 24290431
Narla S, Hsu DY, Thyssen JP, Silverberg JI (2018) Predictors of hospitalization, length of stay, and costs of care among adult and pediatric inpatients with atopic dermatitis in the United States. Dermatitis 29(1):22–31. https://doi.org/10.1097/der.0000000000000323
doi: 10.1097/der.0000000000000323
pubmed: 29059095
Kaufman BP, Guttman-Yassky E, Alexis AF (2018) Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol 27(4):340–357. https://doi.org/10.1111/exd.13514
doi: 10.1111/exd.13514
pubmed: 29457272
Tackett KJ, Jenkins F, Morrell DS, McShane DB, Burkhart CN (2020) Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol 37(1):142–146. https://doi.org/10.1111/pde.14058
doi: 10.1111/pde.14058
pubmed: 31854003
Silverberg JI, Simpson EL (2014) Associations of childhood eczema severity: a US population-based study. Dermatitis 25(3):107–114. https://doi.org/10.1097/der.0000000000000034
doi: 10.1097/der.0000000000000034
pubmed: 24819283
pmcid: 4118692
Chatrath S, Lei D, Yousaf M, Chavda R, Gabriel S, Silverberg JI (2022) Longitudinal course and predictors of depressive symptoms in atopic dermatitis. J Am Acad Dermatol 87(3):582–591. https://doi.org/10.1016/j.jaad.2022.04.061
doi: 10.1016/j.jaad.2022.04.061
pubmed: 35551964
Bell MA, Whang KA, Thomas J, Aguh C, Kwatra SG (2020) Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc 112(6):650–653. https://doi.org/10.1016/j.jnma.2020.06.009
doi: 10.1016/j.jnma.2020.06.009
pubmed: 32641259